OnKure Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- OnKure Therapeutics's estimated annual revenue is currently $3.8M per year.
- OnKure Therapeutics's estimated revenue per employee is $100,500
- OnKure Therapeutics's total funding is $65.8M.
Employee Data
- OnKure Therapeutics has 38 Employees.
- OnKure Therapeutics grew their employee count by 19% last year.
OnKure Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | SVP DMPK and Clinical Pharmacology | Reveal Email/Phone |
4 | SVP Discovery Chemistry | Reveal Email/Phone |
5 | General Counsel, SVP Corporate Affairs & Secretary | Reveal Email/Phone |
6 | Controller | Reveal Email/Phone |
7 | SVP Computational Drug Discovery | Reveal Email/Phone |
8 | SVP Discovery Chemistry | Reveal Email/Phone |
9 | Director, Clinical Systems | Reveal Email/Phone |
10 | Associate Director, Quality Systems and Document Control | Reveal Email/Phone |
OnKure Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 25 | 0% | N/A | N/A |
#2 | $10.3M | 51 | 6% | N/A | N/A |
#3 | $4.4M | 22 | -8% | N/A | N/A |
#4 | $195M | 122 | 0% | $121.4M | N/A |
#5 | $4.8M | 24 | -20% | N/A | N/A |
#6 | $6.8M | 34 | -19% | N/A | N/A |
#7 | $4.8M | 24 | 0% | N/A | N/A |
#8 | $4M | 40 | -11% | $138M | N/A |
#9 | $4.8M | 24 | -14% | N/A | N/A |
#10 | $69.5M | 346 | -6% | N/A | N/A |
What Is OnKure Therapeutics?
OnKure discovers and develops novel cancer therapies through modulation of chromatin/protein acetylation status. Translational studies guide us toward rational drug combinations to exploit synthetic lethalities and pathway re-engagement for defined patient populations.
keywords:N/A
$65.8M
Total Funding
38
Number of Employees
$3.8M
Revenue (est)
19%
Employee Growth %
N/A
Valuation
N/A
Accelerator
OnKure Therapeutics News
2022-04-06 - OnKure Therapeutics Announces Promising Preclinical Data ...
OnKure Therapeutics Announces Promising Preclinical Data on OKI-179 in RAS-Mutated Tumor Models Presented in a Late-Breaking Session at AACR.
2022-03-22 - OnKure Therapeutics to Present Late-Breaking Preclinical ...
OnKure, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that...
Other Companies in Boulder
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.4M | 38 | N/A | N/A |
#2 | $6.9M | 38 | -10% | N/A |
#3 | $4.9M | 38 | 41% | N/A |
#4 | $4M | 38 | -10% | $6.4M |
#5 | $6.1M | 38 | -14% | N/A |